Related Experiment Video
Updated: Jun 1, 2026
12:03
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Status report on carbapenemases: challenges and prospects
1Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.
Expert Review of Anti-Infective Therapy
|May 26, 2011
Summary
Carbapenem-resistant Gram-negative bacteria, a growing threat in healthcare, are often resistant due to carbapenemase enzymes. Few effective treatments exist, necessitating research into new antimicrobial agents.
Area of Science:
- Microbiology and Infectious Diseases
- Antimicrobial Resistance Research
- Clinical Pharmacology
Background:
- Rising antimicrobial resistance in bacterial infections poses significant patient morbidity and mortality risks.
- Carbapenem-resistant Gram-negative bacteria (CRGNB) have increased in prevalence over the last decade.
- Carbapenemase enzymes (classes A, B, and D) are a primary mechanism of resistance, inactivating carbapenems and other beta-lactam antibiotics.
Purpose of the Study:
- To focus on the epidemiology of carbapenemase-producing Gram-negative bacteria.
- To review currently available antimicrobial agents effective against CRGNB.
- To discuss antimicrobial agents in development with potential activity against CRGNB.
Main Methods:
- Epidemiological data review of carbapenemase-producing Gram-negative bacteria.
- Survey of existing antimicrobial therapies for CRGNB infections.
- Analysis of in vitro data for antimicrobial agents under development.
Main Results:
- Carbapenemase production is a key driver of resistance in Gram-negative bacteria.
- Limited therapeutic options are currently available for infections caused by CRGNB.
- Data on novel agents is primarily based on in vitro studies.
Conclusions:
- Carbapenemase-producing Gram-negative bacteria represent a critical and evolving global health threat.
- There is an urgent need for new antimicrobial strategies to combat these resistant infections.
- Continued research and development of effective agents are essential.
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...